Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMELDA: Maintenance Bevacizumab +/- Capecitabine in HER2- MBC
NCT00929240Phase 3Completed
- Sponsor
- Roche
- Start
- Jul 2009
- Primary completion
- Jun 2014
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 11
01
Overview
A Phase 3 trial of capecitabine in breast cancer, sponsored by Roche. Started Jul 2009; status: completed.
02
Drugs
capecitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00929240.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00929240.